{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:39:20Z","timestamp":1780501160998,"version":"3.54.1"},"reference-count":43,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T00:00:00Z","timestamp":1357171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To test aripiprazole for efficacy in decreasing use in methamphetamine\u2010dependent adults, compared to placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Participants were randomized to receive 12 weeks of aripiprazole or placebo, with a 3\u2010month follow\u2010up and a platform of weekly 30\u2010minute substance abuse counseling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>The trial was conducted from<jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>anuary 2009 to<jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>arch 2012 at the San Francisco Department of Public Health.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Ninety actively using, methamphetamine\u2010dependent, sexually active adults were recruited from community venues.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>The primary outcome was regression estimated reductions in weekly methamphetamine\u2010positive urines. Secondary outcomes were study medication adherence [by self\u2010report and medication event monitoring systems (<jats:styled-content style=\"fixed-case\">MEMS<\/jats:styled-content>)], sexual risk behavior and abstinence from methamphetamine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Participant mean age was 38.7 years, 87.8% were male, 50.0% white, 18.9% African American, and 16.7% Latino. Eighty\u2010three per cent of follow\u2010up visits and final visits were completed. By intent\u2010to\u2010treat, participants assigned to aripiprazole had similar reductions in methamphetamine\u2010positive urines as participants assigned to placebo [risk ratio (<jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>) 0.88, 95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>): 0.66\u20131.19,<jats:italic>P<\/jats:italic>\u2009=\u20090.41]. Urine positivity declined from 73% (33 of 45 participants) to 45% (18 of 40) in the placebo arm and from 77% (34 of 44) to 44% (20 of 35) in the aripiprazole arm. Adherence by<jats:styled-content style=\"fixed-case\">MEMS<\/jats:styled-content>and self\u2010report was 42 and 74%, respectively, with no significant difference between arms (<jats:styled-content style=\"fixed-case\">MEMS<\/jats:styled-content>\u2005<jats:italic>P<\/jats:italic>\u2009=\u20090.31; self\u2010report<jats:italic>P<\/jats:italic>\u2009=\u20090.17). Most sexual risk behaviors declined similarly among participants in both arms (all<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). There were no serious adverse events related to study drug, although participants randomized to aripiprazole reported more akathisia, fatigue and drowsiness (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared with placebo, aripiprazole did not reduce methamphetamine use significantly among actively using, dependent adults.<\/jats:p><\/jats:sec>","DOI":"10.1111\/add.12073","type":"journal-article","created":{"date-parts":[[2012,11,27]],"date-time":"2012-11-27T23:16:42Z","timestamp":1354058202000},"page":"751-761","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Aripiprazole for the treatment of methamphetamine dependence: a randomized, double\u2010blind, placebo\u2010controlled trial"],"prefix":"10.1111","volume":"108","author":[{"given":"Phillip Oliver","family":"Coffin","sequence":"first","affiliation":[{"name":"San Francisco Department of Public Health San Francisco California USA"},{"name":"University of California San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn\u2010Milo","family":"Santos","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health San Francisco California USA"},{"name":"University of California San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moupali","family":"Das","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health San Francisco California USA"},{"name":"University of California San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre M.","family":"Santos","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Huffaker","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Matheson","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gasper","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vittinghoff","sequence":"additional","affiliation":[{"name":"University of California San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant N.","family":"Colfax","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health San Francisco California USA"},{"name":"University of California San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,3]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"United Nations Office on Drugs and Crime (UNODC).World Drug Report 2012 UNODC. New York: United Nations Office on Drugs and Crime 2012."},{"key":"e_1_2_6_3_1","series-title":"NSDUH Series","first-page":"13","volume-title":"Office of Applied Studies","author":"United States Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2010"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60753-2"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2011.587390"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03639.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.010"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.4.713"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.56"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.47"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.64"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0022-3565(24)35115-8","article-title":"Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors","volume":"291","author":"Volkow N. D.","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0211220"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300169"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.05.011"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/22560"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-199212000-00008"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(01)00472-5"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(01)00124-7"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.06.006"},{"key":"e_1_2_6_21_1","unstructured":"ReidM.S. PalamarJ. FlamminoJ. MahoneyJ.J. De La GarzaR. NewtonT. F.et\u2009al.A double\u2010blind placebo\u2010controlled assessment of aripiprazole effects on methamphetamine craving: longitudinal and cue reactivity studies.Paper presented at the The College on Problems of Drug Dependence 68th Annual Scientific meeting Scottsdale Arizona 17\u201322 June2006; abstract #644; Available athttp:\/\/www.cpdd.vcu.edu\/Pages\/Meetings\/Meetings_PDFs\/2006abstractbook.pdf(accessed 13 December 2012)."},{"key":"e_1_2_6_22_1","unstructured":"De la GarzaR. ReidM. S. PalamarJ. MahoneyJ.J. FongT. ElkashefA.et\u2009al.A double\u2010blind placebo\u2010controlled assessment of potential interactions between intravenous methamphetamine and aripiprazole: preliminary finidings.Paper presented at the College on Problems of Drug Dependence (CPDD) Conference Orlando FL June2006; abstract #591; Available athttp:\/\/www.cpdd.vcu.edu\/Pages\/Meetings\/Meetings_PDFs\/2006abstractbook.pdf(accessed 13 December 2012)."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300803"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.02.004"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318221b2db"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000169419.38899.5b"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0613"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S"},{"key":"e_1_2_6_29_1","volume-title":"Structured Clinical Interview for DSM\u2010IV\u2010TR Axis I Disorders\u2010Non\u2010Patient Edition (SCID\u2010I\/NP, 1\/2007 Revision)","author":"First M. B.","year":"2007"},{"key":"e_1_2_6_30_1","first-page":"1","article-title":"Revised guidelines for HIV counseling, testing, and referral","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_6_31_1","volume-title":"Relapse Prevention Treatment for Cocaine Addiction: The RPT\u2010C Manual","author":"Brief D.","year":"1998"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011396711486"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/152.2.99"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh135"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1467"},{"key":"e_1_2_6_36_1","unstructured":"Division of AIDS (DAIDS).Table for grading severity of adult adverse experiences for the HIV prevention trials network. Bethesda MD: National Institute of Allergy and Infectious Diseases Division of AIDS;2003."},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2011.00263.x"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.124"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02717.x"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.07.007"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145708009097"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.1.160"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.3109\/13651501.2012.667116"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1010654108"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.12073","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.12073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T22:03:47Z","timestamp":1745359427000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.12073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,3]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/add.12073"],"URL":"https:\/\/doi.org\/10.1111\/add.12073","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,3]]},"assertion":[{"value":"2012-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-11-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}